Denmark’s largest pension fund has boosted its stake in Novo Nordisk A/S this year, betting the obesity drugmaker will outpace rivals beyond the US market where its struggles have led to two profit ...
Novo Nordisk stock has dropped to multiyear lows due to slower obesity drug uptake, strong competition from Eli Lilly, and continued sales of alternatives. A revival for Novo’s stock depends on ...
Novo Nordisk’s Q2 2025 results showed resilient revenue growth, but profit guidance was cut due to U.S. competition, compounded drugs, and currency headwinds. I see the upcoming Q3 earnings and ...
As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion. Until 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback